🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed/Refractory T-cell Lymphoma

CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CD180 CART Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies NCT07284433Phase 1, Phase 213 sites📍 Chicago📍 Evanston📍 Providence AvenCell Therapeutics, Inc. · Tests: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690Phase 12 sites📍 Houston📍 Houston Baylor College of Medicine · Tests: C7R.CD30.CAR-EBVST cells Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma NCT07763210Phase 21 site📍 Nashville Vanderbilt-Ingram Cancer Center · Tests: Therapeutic Hydrocortisone, Cytarabine, Dexamethasone, Methylprednisolone, Cyclophosphamide SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site📍 Prague Institute of Hematology and Blood Transfusion, Czech Republ… · Tests: Autologous CAR19 T lymphocytes VHAG in Treating R/R T-ALL/LBL NCT06742463Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: Venetoclax, homoharringtonine, Cytarabine (Ara-C), G-CSF Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site📍 Beijing Peking University People's Hospital · Tests: CD5-targeted CAR-T cells CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia NCT07328503Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies NCT07101705EARLY Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: OriV508 Injection Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies NCT06316427Phase 1, Phase 24 sites📍 Beijing📍 Shanghai📍 Shanghai Beijing GoBroad Hospital · Tests: Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia NCT07361029Phase 11 site📍 Riyadh King Faisal Specialist Hospital & Research Center · Tests: CAR T cells chimeric antigen receptor cells Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia NCT03263572Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Blinatumomab, Cytarabine, Methotrexate, Ponatinib A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL NCT05514327NA1 site📍 Beijing Peking Union Medical College Hospital · Tests: ultra-fraction radiotherapy Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies NCT05887167Phase 11 site📍 Los Angeles Joshua Sasine, MD, PhD · Tests: autologous hematopoietic stem cells added to planned CAR T Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL NCT07013565Phase 21 site📍 Valhalla New York Medical College · Tests: Vinblastine (Velban), Brentuximab vedotin (Adcetris), Nivolumab (Opdivo) CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors NCT06365671Phase 21 site📍 Shanghai Ruijin Hospital · Tests: autologous stem-cell transplantation, Relmacabtagene autoleucel (relma-cel) GVM±R in Patients With Relapsed or Refractory Aggressive NHL. NCT06244368Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: GVM±R regimen Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527Phase 17 sites📍 Duarte📍 Chicago📍 New York AIDS Malignancy Consortium · Tests: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL NCT06966154Phase 1, Phase 21 site📍 Shanghai Fudan University · Tests: tislezumab, golidocitinib, Selinexor Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726Phase 21 site📍 Seattle University of Washington · Tests: Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Ther… Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma NCT07097207Phase 1, Phase 21 site📍 Shenzhen Shenzhen University General Hospital · Tests: CAR-T cell CD45BE-HSPC + CART-45 Cells NCT07451054Phase 11 site📍 Philadelphia University of Pennsylvania · Tests: CART-45 cells, CD45BE-HSPC A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) NCT07072169Phase 11 site📍 Shanghai Ruijin Hospital · Tests: ABO2203 Injection A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) NCT06207123Phase 1, Phase 22 sites📍 Chicago📍 Rochester University of Chicago · Tests: LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate CD-19 CAR-T Cell for Pediatric ALL or Lymphoma NCT06866873NA1 site📍 Hong Kong Hong Kong Children's Hospital · Tests: CAR-T MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia NCT07371403NA1 site📍 Amman King Hussein Cancer Center · Tests: MB-CART19.1 CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319Phase 11 site📍 Boston Marcela V. Maus, M.D.,Ph.D. · Tests: CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies NCT06528301Phase 19 sites📍 Duarte📍 Chicago📍 Grand Rapids Umoja Biopharma · Tests: UB-VV111, rapamycin A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL NCT06855823Phase 1, Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Golicitinib combined with Pomadomide
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy